Draig Therapeutics

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Delix

This company develops non-hallucinogenic neuroplasticity-promoting medicines to treat neuropsychiatric and neurodegenerative conditions for patients with brain disorders.

Autobahn Therapeutics

This company develops brain-penetrating small molecule therapies for patients with neuropsychiatric and neuroimmunologic disorders, including depression and multiple sclerosis.

Delix Therapeutics

This biotechnology company develops non-hallucinogenic neuroplasticity-promoting medicines to treat patients with neuropsychiatric and neurodegenerative conditions.

Beckley Psytech

The company develops psychedelic-derived medicines to treat patients with neurological and psychiatric conditions such as treatment-resistant depression and rare headache disorders.